Part of funding portal member: truCrowd, Inc.
Mobile Menu

Gulf Coast Canna Meds, Inc

Medical Marijuana Grower, Extractor and Dispensary. Soon.

Closed on 05/01/18
Minimum target reached (accepting oversubscriptions)



funding goal 

Reg CF

exemption used 


pre money valuation 


min investment 


amount committed 



Investment Type

SAFE+REV, or Simple Agreement for Future Equity and a Revenue Participation Rights and have two exits: the Revenue Participation that will give you 3X multiple return on your money, and the second one is the SAFE that will convert your money into equity when we will go public or get bought.

Safe: Simple Agreement for Future Equity

$8.1 Mil Valuation Cap

rev: revenue participation

5% Revenue Split, 3x Returns

Why invest in legal cannabis?

National Cannabis Market Sales & Projections ($ in Billions)
  • The legal cannabis industry is the fastest growing industry in America
  • National sales soared to $6.7 billion in 2016, up 17.4% from 2014 (ArcView Market Research.)
  • The legal market is expected to grow to $10 billion in sales for 2017, and by 2021 nearly $22.6 billion nationally.

And the industry is only in its infancy. Many states have begun or passed legislation but lack the infrastructure for growers, processing facilities, and retail dispensaries.


Top 5 U.S. Medical Cannbis Markets in 2020
Florida is poised to be the 2nd largest market
  • Florida is the third largest state by population (20.3 million and growing (Bureau of Economic and Business Research at the University of Florida.)
  • Florida has the highest proportion of the population over the age of 65 (19.1%) matching the demographic market for medical cannabis.
  • Florida's patients registry with the Office of Medical Marijuana Use has grown from 17K to 64K in the past six months. (276% Growth)
  • Florida Senate Bill 8-A, passed July (2017), expanded the patient's treatable conditions from two to nine.
  • Five more companies have been licensed already and nine more companies will be licensed to produce and distribute products across the state.
  • And when the patient registry reaches 100K, more company licenses are slated to issue.

Best of all

Aside from the aging population, Florida is a great medicinal cannabis market because

  • Growing conditions can be made favorable in Florida
  • The barriers to entry for non-Florida companies are fierce. Due to the requirement for vertical integration- all growing, processing, and dispensing are the responsibility of the license-holder. The threat of interstate market share is unlikely.

Why invest with Gulf Coast Canna Meds?

THE Most Prestigious Medical Cannabis Dream Team

The Florida market is poised to explode in the medical cannabis industry that is already booming in its infancy around the country. Gulf Coast Canna Meds is THE Dream Team of national experts with the premier reputations to navigate the logistics in all facets of cannabis cultivation and sales including: operations, security, business leadership, legal, healthcare, finance, accounting, formulation, franchising, lobbying and more. GCCM was formed by industry leaders to win one of the select Florida licenses which requires strict and rigorous criteria including vertical integration (cannabis cultivation, processing, and dispensing by one company.)

vertical integration noun the combination in one company of two or more stages of production normally operated by separate companies.

Upon receiving one of the recently expanded Florida licenses (Florida legislature Senate Bill 8A and Amendment 2), GCCM will operate a cultivation facility, processing facility and a dispensary/treatment center in the Tampa-St. Petersburg- Clearwater metro area. Florida has great opportunity in legal cannabis is already expected to be the 2nd largest market in the country. Gulf Coast Canna Meds intends to be the community leader and future standard of excellence in cultivation, extraction, and cannabis dispensing in Florida. Our competitive advantages include: Florida agriculture experience, cultivation methods including organic hydroponics, formulations licensed from the world-leader in medical cannabis (Constance Therapeutics), educational approach to patients, confidentiality, security and enterprise management.

Investment Type

SAFE+REV, or Simple Agreement for Future Equity and a Revenue Participation Rights and have two exits: the Revenue Participation that will give you 3X multiple return on your money, and the second one is the SAFE that will convert your money into equity when we will go public or get bought.

Safe: Simple Agreement for Future Equity

$8.1 Mil Valuation Cap

rev: revenue participation

5% Revenue Split, 3x Returns

The 6-part Gulf Coast Canna Meds formula for success

In accordance with licensing requirements, Gulf Coast Canna Meds (GCCM) will run a vertically integrated medical cannabis business, to include cultivation, extraction, processing, manufacturing, distribution, and dispensing operations. GCCM will cultivate unique strains with distinct cannabinoid profiles and produce finished products such as medical cannabis concentrates, vaporizer cartridges, topicals and other infused products. GCCM will sell its branded products at its own dispensary locations and to other MMTCs around the state of Florida.
GCCM will cultivate seeds and clones of popular strains to add to the company's product line. GCCM's breeding program will create signature strains that have specific benefits for various qualifying conditions. The breeding program will focus exclusively on breeding plants that contain the cannabinoid ratios needed to alleviate the suffering of patients. Feedback from local physicians, patients, and other MMTCs will be essential for guiding the breeding project.
GCCM will internally cultivate all the cannabis used in the production of its medical cannabis products. This practice will ensure that all constituent materials meet GCCM's rigorous quality standards and will maintain consistency throughout the product line and earn consumer and medical trust. Consumers will develop product loyalty and be able to reorder the products with consistent results.
GCCM plans to operate multiple dispensaries. The company will maintain a competitive edge by offering diverse products with various cannabinoid compositions that originate from GCCM cultivation and processing facilities. As a result of the vertical integration of GCCM operations, the company will offer superior products compared to dispensaries relying on wholesale vendor accounts to supply medical cannabis. GCCM will provide the highest quality product in the market and be known as the trusted source and obvious choice in a new market.
GCCM's Skilled dispensary technicians will assist patients in personable, face-to-face interactions. GCCM dispensaries will fully accommodate people with disabilities and the elderly, two critical demographics about whom GCCM cares deeply in regard to quality of life. GCCM dispensaries will be sleek, clean, and designed like a modern pharmacy.
As part of the GCCM dispensary experience, dispensary technicians will make sure to accommodate all inquiries about medical cannabis. GCCM will take care to protect patient data and guarantee privacy when serving patients, and the company's inventory systems will ensure a complete seed-to-sale traceability. This practice will streamline company operations and demonstrate responsibility at each step of production.

Invest in the dream Team

Lori Daugherty


With 25+ years experience, Lori is a proven senior executive/CEO revered in the medical industry for enterprise strategies to improve financial performance, drive customer penetration with revenue growth 30%+, and increase bottom line growth (more than 25% in just 6 months.)

Lori's operational, financial, and strategic genius has benefited more than a dozen organizations for whom she has served in an executive or Board position.

With a very successful history of overhauling, streamlining, restructuring, merging, acquiring, and navigating private equity for organizations at the $450 M revenue-size, Lori has agreed to captain GCCM's venture. She recognizes the tremendous business and humanitarian opportunity in Florida in the medical cannabis market.

Lori's vast professional experience in the hospice industry and home health, as well as, personal experience caring for terminally ill friends and family fuels Lori's passion to provide reputable medical cannabis solutions. She has witnessed the traditional medicinal struggle between extreme pain and extreme pain control which destroys the patient's quality of life. She strives to bring reputable standardization and coaching to eliminate the stigma of medicinal cannabis.

David Kitenplon

Chief Financial Officer

Dave has been a Senior Vice President and managing partner in many investment, construction and real estate companies. Before his extensive finance career, Dave created sales presentations for the world's largest IT company and installed the first proprietary Florida Bank ATM system. He serves on Board of Directors for Largo Medical Center and is involved in various community projects.

Michael Welch

Chief Marketing Officer

Michael enjoyed a long career in marketing, advertising and production and is now responsible for public affairs and community outreach for Gulf Coast Canna Meds.

Cannabis is one of nature's greatest gifts for health and wellness, and he appreciates the opportunity to be involved with Gulf Coast Canna Meds, a company dedicated to the public good.

Lonnie Orns

Chief Operations Officer

With over 25 years operating a premiere national franchise, Lonnie and his team grew from 5 locations to three businesses and 92 locations. As a sales and expansion franchise expert Lonnie's companies have won numerous awards for sales, operations, and innovation in growth.

Andrew E. Hano

Medical Director

Andrew is a hematologist/medical oncologist in Pinellas County, Florida for 32 years, retiring from private practice in 2015. He is recognized as honorary staff at Largo Medical Center and a member of the American Society of Clinical Oncology and the American Osteopathic Association.

Oscar Mouton

Chief Security Officer

Oscar is a highly-decorated former Detective from Washington D.C. and a former United States Marine. Oscar has served three tours of duty in Afghanistan as a DOD contractor. Oscar is a specialist in communication and intelligence and was deputized with the Department of Justice. His awards include merits of service, letters of commendation and more.

Greg Kosater R.Ph.

Chief Clinical Officer

Greg Kosater is a registered pharmacist with over 35 years of experience in the healthcare industry. Greg has extensive experience in both the clinical and operational aspects of retail, PBM, workers' compensation and the hospice and palliative care lines of business. Greg has numerous professional affiliations including the University of Georgia's College of Pharmacy Advisory Board

The Dream Advisory Team

  • Canna Advisors - the #1 cannabis consulting firm, assists entrepreneurs win licenses, optimize facility design, standardize operations, maximize business development and more
  • Constance Therapeutics - the premier national physician-recommended award-winning and patent-pending medicinal cannabis brand; makes the best standardized medicinal cannabis extracts in the industry
  • Landmarc Strategies and Paladino Public Affairs - our well respected Florida lobbyists based in Tallahassee & Tampa Bay
  • Florida for Care - founded in 2014 to advocate for the implementation of a strong, well-regulated, Florida medical marijuana system under Amendment 2
  • Battaglia, Ross, Dicus & McQuaid, P.A. - corporate legal counsel
  • Cohen Kotler, P.A. - cannabis legal counsel
  • McAtee & Associates, CPAs, P.A. - business accounting firm
  • We have secured the mentoring of Canna Advisors and brought them on the team. Canna Advisors is the pre-eminent cannabis consulting firm in the nation. They have helped more businesses win licenses, navigate the cannabis regulatory environment, and advocate for the cannabis industry.
  • In February, the National Cannabis Industry Association (NCIA) presented Canna Advisors with their Industry Excellence Award for upholding exemplary community engagement, political advocacy and education within the industry
  • Canna Advisors was ranked the #1 Cannabis Consulting Company by the CBE (Cannabis Business Executive)
  • The firm's winning history includes dozens of license wins spanning 20 competitive markets.
  • Canna Advisors continues to set new benchmarks for success with its professional team, offering more than 70 years of combined regulatory experience.

Constance Finley

Constance Finley, founder of Constance Therapeutics, after suffering from a debilitating auto-immune disorder and following a harrowing regimen of traditional treatment, turned to growing her own strains of legal medical cannabis despite her concerns regarding the stigma. After recovering her own quality of life, doctors referred patients suffering from a variety of illnesses to Constance for relief and Constance Therapeutics was born. Through standardization and ISO 9000 pharmaceutical techniques, Constance Therapeutics has been able to provide a consistent brand through a patented process.

About Constance Therapeutics

Constance Therapeutics is a vertically integrated medicinal cannabis company producing standardized and science-based whole-plant cannabis extracts. The company has created a new category of whole-plant cannabis extracts that fills the gap between traditional pharmaceuticals and commonplace cannabis products, providing much needed additional treatment options to physicians and their patients.

Constance Therapeutics' extracts are derived from fully trimmed, female unfertilized cannabis flowers of plants with known genetics using certified-organic, pharmaceutical-grade ethanol via a highly controlled, quantitatively-defined and patented process that is based on solid scientific and engineering principles. Extracts are systematically third-party tested and routinely cross-tested in the industry's most respected laboratories. Since 2008, the company has employed stringent, science-based processes and standards to ensure the highest quality and consistency.


CT pioneered the 4:1 ratio broadly adopted for cancer in the industry, and later the 1:1 ratio now pervasive in the industry; founder Constance Finley led the first-ever SXSW panel on cannabis in 2015; and CT received the first cannabis manufacturing permit in the city of San Francisco.

"If you find something that helps, we can do it again, exactly the same, from the same grower, from the same genetics, to the exact same measurements by weight, so that you can find a reliability." - Constance Finley

Constance Finley is an international speaker on topics such as "Taking cannabis seriously" and "The Future of Botanical Medicine".

Now is the time for medicinal cannabis


  • Recent regulatory momentum in the Florida medical cannabis industry makes it an opportune time to invest in the market.
  • On June 9th, the Florida Legislature approved a bill establishing a framework for the state's constitutional amendment expanding medical marijuana.
  • The bill was officially signed into law by Governor Rick Scott on June 23rd, 2017.
  • Current regulation requires cannabis distributors to be vertically-integrated in order to secure a license to sell medical marijuana in Florida.
  • The company is a member of Florida for Care and has hired Tallahassee & Tampa Bay based lobbyists to represent the company and to stay abreast of all regulatoryactions and maneuvers.

Recent Medical Marijuana Headlines in Florida

Florida Legislature finally passes medical marijuana bill

First Coast News-Jun 10, 2017

Gov. Rick Scott signs medical marijuana bill into law

Orlando Sentinel-Jun 23, 2017

What are the current stats on Florida medicinal cannabis?

OMMU by the Numbers Current Total
Patients in the Registry 83,503
New patients in last 2 weeks 2,384
Qualified Physicians 1,186
Approved Medical Marijuana Treatment Centers 13
Approved Retail Dispensing Locations 28

Note: The medical cannabis environment is changing rapidly with new updated numbers every day. For the latest updates, information and counts on licenses, patient registrations and active facilities in Florida, see the Office of Medical Marijuana Use link here:

Frequently asked questions on medical cannabis can be found at the bottom of the page

Now is the time for medicinal cannabis...did you know...

  • Medical cannabis is more than mainstream in its popular acceptance.
  • Cannabis is now legal in 30 U.S. states plus the District of Columbia.
  • While states have legalized cannabis in sweeping fashion, they are still working out the laws and practices for licensing, sourcing, distribution, taxation, and regulation of legal cannabis. No single brand has emerged as the dominant market share force.
  • American opinion is 94% in favor of medical cannabis and 75% of Americans oppose federal government interference with states that have approved it. (Quinnipiac University Poll, August 3, 2017)

The medical benefits of cannabis

The healthful properties are available for the first time since the 1930's

While the FDA has not recognized or approved the cannabis plant as medicine, as the FDA would require many more clinical trials to assess the benefits and detriments, they have approved two medications that contain cannabinoid chemicals. Cannabidiol, CBD, a non-psychoactive, non-toxic chemical in cannabis, has been suggested to stop cancer cells from spreading. (2007 study by Molecular Cancer Therapeutics) Scientists are currently conducting preclinical and clinical trials with cannabis and its extracts to treat the symptoms of:

  • diseases that affect the immune system, including HIV/AIDS and multiple sclerosis (MS), which causes gradual loss of muscle control
  • inflammation
  • pain
  • seizures
  • substance use disorders
  • mental disorders

Medical cannabis has been used to treat:

  • Temporary pain and soreness
  • Neuromuscular discomfort
  • Sleeplessness
  • Seizures
  • Muscular Sclerosis
  • Post Traumatic Stress Disorder
  • and more

Benefits of Medical Cannabis (with no side effects)

Have you heard of the human (ECS) endocannabinoid system?

Like the circulatory system, the respiratory system, and the lymphatic system, the endocannabinoid system is a biological system in humans. Composed of endogenous lipid-based retrograde neurotransmitters throughout the nervous system and brain, the ECS regulates important processes:

  • fertility
  • appetite
  • sleep
  • pain-sensation
  • mood
  • Memory

Cannabinoids promote homeostasis in many human systems. Cannabis contains at least 113 cannabinoids including CBD (cannabidiol) and THC which researchers suggest support the human endocannabinoid system in a variety of ways. With the legalization of cannabis, homeopathy has a renewed interest in the supplemental and/or healing effects of cannabis. The CBD market now legal in 50 states is rapidly growing and estimated to be a $2.1 billion market in 2020 (700% growth in 4 years.)

Medical cannabis provides relief from the opioid epidemic

  • The United States sees more than 12.7 million new cancer cases a year1 - and among those who must undergo surgery, one in 10 will become dependent on opioid pain relievers2.
  • America's opioid epidemic kills 116 people everyday from lethal overdoses and dependence on pain medications is a close rival to cancer itself as a serious threat to patients' lives.
  • 2.1 million people have an opioid use disorder3.
  • More than 3 out of 5 drug overdose deaths in the U.S. involve an opioid4.
  • International Agency for Research on Cancer (IARC)
  • University of Michigan
  • U.S. Department of Health and Human Services
  • Centers for Disease Control

Better pain management alternatives are available in medical cannabis

A new study published in the European Journal of Internal Medicine, explored the effectiveness of cannabis for cancer patients.

"Cannabis is a very good alternative to reduce opioid consumption, to increase quality of life, and to reduce pain, nausea and vomiting," says Lihi Bar-Lev Schleider, lead researcher on the study.

"If you look at this study and you're a doctor and your patients are suffering with opioids, you'd be hard pressed not to give them cannabis . . . The same for steroids, or any sleep medication. You see the quality of life was so staggering that you should consider cannabis."

Sid Taubenfeld, CEO of Tikun Olam Pharma, United States


GCCM aims to be a vertically-integrated distributor of a complete offering of medical cannabis products to the Florida market. Below is a representative sample of the Company's product offerings.

These products are created using chilled ethanol to extract cannabinoids such as THC and CBD. This allows for more controlled formulations and higher cannabinoid levels than those traditionally found in raw flowers.
These products are created without using traditional solvents to extract the chemical compounds of the plant. This allows for more controlled formulations and higher cannabinoid levels than those traditionally found in flowers.
Vaporizers and other devices that allow patients to easily inhale medicinal vapor from cannabis flower or concentrated oils have become popular options for medicating.
Cannabis infused lotions, balms, oils, salves or patches that are absorbed through the skin and provide localized relief to areas of the body where they are applied. Most topical products do not yield any psychoactive effect.
Stable food grade chilled ethanol-based infusions (i.e. olive oil or coconut oil) that are ingested orally or absorbed sublingually. They can be easily formulated to allow patients maximum control over dosing and symptom relief.
Infused capsules, tablets and liquids that contain cannabis extract, which is digested and absorbed into the bloodstream through the digestive tract. These products are expected to be popular in Florida because they are common and long-established forms of medication
Items that feature the company logo, including, but not limited to: clothing, hats and caps, other wearable accessories such as sunglasses, branded vaporizer pen batteries, etc.

Already in place


With our team in place we already raised $200,000 from our founders and started the licensing procedure. We are working with Canna Advisors, known for the high success rate in licenses approval and partner with Constance Therapeutics, the world leader in Medical Marijuana.

The Advisory Team

Canna Advisors was named the #1 Consulting Firm in 2017 by Cannabis Business Executive. The company has helped drive policy and consulted emerging businesses across the world and is known nationally for their high success rate in securing medical marijuana licenses. They only work with a limited number of well-qualified group.

Constance Therapeutics

Constance Therapeutics produces whole plant cannabis extracts as part of an integrative approach to treatment. It is the first cannabis extraction producer to be awarded a manufacturing permit in the city of San Francisco, California. The company has implemented extensive Standard Operating Procedures (SOPs) and is currently implementing internationally accepted standards for pharmaceutical companies (ISO 9000)

Secured Property

Our team has secured property for cultivation, a 34,000 foot warehouse retrofitted for indoor grow in addition to a 10,0000 square foot green house. We've secured an ideal extraction location, plus two prime dispensary locations which meet zoning approval requirements.

Affiliations industry connections

Use of proceeds

Proceeds from the fundraising will be used for working capital, marketing and promotional expenses, inventory, product development, community outreach and educational information, mergers/acquisitions, and general corporate expenses.

When Target Amount Raised

Operation Expenses 20.0%

When Max. Amount Raised

Operation Expenses 20.0%


Lori Daugherty
Lori Daughertyone year ago
  1. How many vertically integrated Medical Marijuana Treatment Center (“MMTC”) licenses have been issued in Florida?
  2. As of February 23, 2018, there are 13 approved MMTC licenses with a combined total of 27 approved dispensary locations, and those dispensary locations are all owned by only 5 of the 13 approved MMTC. The other 7 MMTC have yet to open a dispensary. 


  1. How many dispensaries may an approved MMTC operate?
  2. Licensed MMTC may not establish or operate more than 25 dispensing facilities unless the patient registry reaches more than 100,000 patients at which time, and at the time of each additional 100,000 patients, the statewide maximum number of dispensing facilities per MMTC increases by 5.


  1. How many more MMTC licenses are expected and when?


  1. Originally, 7 licenses were approved in 2014 under the low-THC rules. In 2017, pursuant to Senate Bill 8A, the legislation required the Department of Health (“DOH”) to issue licenses to an additional 10 applicants.  First priority of those ten applicants went to applicants that applied in 2014 under the low THC rules and whose application was reviewed but denied a license and that is how the additional 6 licenses were granted in 2017.  According to 8A, by October 3, 2017, the DOH was to license the remaining of the 10 (thus 4) applicants that met the criteria in 8A, plus name an additional 4 “contingent” licenses based on patient count.  The additional 4 contingent MMTC’s were to be licensed within 6 months of the patient register reaching 100,000 patients, and furthermore, an additional 4 MMTC’s are to receive a licensure within 6 months of each additional 100,000 patients.   Obviously the DOH has failed to meet these October 2017 deadlines and there is currently uncertainty as to when they will meet these requirements imposed by 8A.  Thus, upon the patient count reaching 100,000 there should be 8 new licenses issued with 4 more contingently named and ready to proceed upon the patient count reaching 200,000.    Furthermore, an additional 4 MMTCs will be licensed within 6 months of each additional 100,000 patients.


  1. What restrictions may a county/municipality place on a MMTC’s operation?


  1. Generally, the regulation of cultivation, processing, and delivery of marijuana is preempted to the state except that an MMTC may not be located within 500 feet of the real property of a public or private elementary, middle, or secondary school unless a city or county determines that the location promotes the public health, safety, and general welfare of the community. However, the MMTC application does require “preapproval” from the city/municipality in which it intends to cultivate and a local jurisdictions may ensure that MMTC facilities comply with the Florida Building Code, the Florida Fire Prevention Code etc.


In regard to dispensaries, a county or a municipality may ban MMTC dispensing facilities from locating within the boundaries of that county or municipality but - absent a complete ban of dispensing facilities- a county or municipality may not otherwise restrict the number of dispensing facilities that may locate within that county or municipality.  Fortunately, the City of St Petersburg has been working with us favorably in establishing our facilities here in Pinellas County.


  1. What is the current patient/doctor ratio and how can I track the current status?


  1. As of March 2, 2018, the ratio is 83,503 registered patients and 1,186 qualified physicians.  The Florida Department of Health, Office of Medical Marijuana provides weekly updates as to those numbers on the following link:

Load More


Unfortunately, this securities offering is closed. For questions, please email Thanks!

David Jackson
David Jackson - Investor4 months ago
How do I add to my investment?
Reginald Weaver
Reginald Weaver - Investor6 months ago
under crowdfunding can your investments be transferred from like real estate to dispensary?
Jorge L Garcia
Jorge L Garcia - Investor8 months ago
I have not been refunded my original investment, could you please check what is causing the delay?
Jorge L Garcia
Jorge L Garcia - Investor   
Never mind, I see now that you refunded my funds. Thanks and good luck.

8 months ago
Oscar De La Rosa
Oscar De La Rosa - Issuer    
I have not been refunded my original investment, I will like to get an update please

7 months ago
Lori Daugherty
Lori Daugherty - Issuer    
Good afternoon Oscar,

All funds have been returned at this point in time. There may be an issue with your address or account number used to return those funds so please contact us via email at And we can take care of everything over email so your personal information is kept private.

7 months ago
Load More


Form C and Offering Statement View Download
Valuation Report View Download

Other Disclosures

Read the Form C filed with the SEC for other important disclosures, like financial statements, Directors, Officers, shareholders with more than 20% of voting rights, and more.
Use of Proceeds
The allocation of the use of proceeds among the categories of anticipated expenditures represents management’s best estimates based on the current status of the Company’s proposed operations, plans, investment objectives, capital requirements, and financial conditions. Future events, including changes in economic or competitive conditions of our business plan or the completion of less than the total Offering, may cause the Company to modify the above-described allocation of proceeds. The Company’s use of proceeds may vary significantly in the event any of the Company’s assumptions prove inaccurate. We will retain broad discretion in the allocation of the net proceeds from this Offering, reserve the right to change the allocation of net proceeds from the Offering as unanticipated events or opportunities arise and could utilize the proceeds in ways that do not necessarily improve our results of operations or enhance the value of our Common Stock. Additionally, the Company may from time to time need to raise more capital to address future needs that we may not have anticipated as of the date of this Offering Circular.
Special Note Regarding Forward-Looking Statements
This offering contains forward-looking statements within the meaning of the federal securities laws. We caution investors that any forward-looking statements presented in this offering, or which management may make orally or in writing from time to time, are based on the Company’s beliefs and assumptions made by, and information currently available to, the Company. When used, the words “anticipate,” “believe,” “expect,” “intend,” “may,” “might,” “plan,” “estimate,” “project,” “should,” “will,” “would,” “result” and similar expressions, which do not relate solely to historical matters, are intended to identify forward-looking statements. Such statements are subject to risks, uncertainties and assumptions and are not guarantees of future performance, which may be affected by known and unknown risks, trends, uncertainties and factors that are beyond the Company’s control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. While forward-looking statements reflect the Company’s good faith belief when made, they are not guarantees of future performance. The Company expressly disclaims any responsibility to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this offering may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We undertake no obligation to revise or publically release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements.

Back to top